EP1667695A4 - Oligonucleotides ciblant les maladies a prions - Google Patents

Oligonucleotides ciblant les maladies a prions

Info

Publication number: EP1667695A4
Authority: EP; European Patent Office
Prior art keywords: prion diseases; oligonucleotides targeting; targeting prion; oligonucleotides; diseases
Prior art date: 2003-09-11
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.): Withdrawn

Application number

EP04787566A

Other languages

German (de)

English (en)

Other versions

EP1667695A2 (fr

Inventor

Jean-Marc Juteau

Andrew Vaillant

Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)

Replicor Inc

Original Assignee

Replicor Inc

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2003-09-11

Filing date

2004-09-10

Publication date

2007-01-31

2003-09-11 Priority claimed from PCT/IB2003/004573 external-priority patent/WO2004024919A1/fr

2004-09-10 Application filed by Replicor Inc filed Critical Replicor Inc

2006-06-14 Publication of EP1667695A2 publication Critical patent/EP1667695A2/fr

2007-01-31 Publication of EP1667695A4 publication Critical patent/EP1667695A4/fr

Status Withdrawn legal-status Critical Current

Links

108091034117 Oligonucleotide Proteins 0.000 title 1
208000024777 Prion disease Diseases 0.000 title 1
JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 title 1
230000008685 targeting Effects 0.000 title 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7088—Compounds having three or more nucleosides or nucleotides
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/115—Aptamers, i.e. nucleic acids binding a target molecule specifically and with high affinity without hybridising therewith ; Nucleic acids binding to non-nucleic acids, e.g. aptamers
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/10—Type of nucleic acid
- C12N2310/16—Aptamers
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/31—Chemical structure of the backbone
- C12N2310/315—Phosphorothioates

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Chemical & Material Sciences (AREA)
Engineering & Computer Science (AREA)
Organic Chemistry (AREA)
Genetics & Genomics (AREA)
Biomedical Technology (AREA)
General Health & Medical Sciences (AREA)
Bioinformatics & Cheminformatics (AREA)
Pharmacology & Pharmacy (AREA)
Molecular Biology (AREA)
Animal Behavior & Ethology (AREA)
Medicinal Chemistry (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
General Chemical & Material Sciences (AREA)
Wood Science & Technology (AREA)
Zoology (AREA)
Chemical Kinetics & Catalysis (AREA)
General Engineering & Computer Science (AREA)
Biotechnology (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Physics & Mathematics (AREA)
Biophysics (AREA)
Communicable Diseases (AREA)
Neurosurgery (AREA)
Plant Pathology (AREA)
Microbiology (AREA)
Neurology (AREA)
Oncology (AREA)
Biochemistry (AREA)
Epidemiology (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

EP04787566A 2003-09-11 2004-09-10 Oligonucleotides ciblant les maladies a prions Withdrawn EP1667695A4 (fr)

Applications Claiming Priority (3)

Application Number	Priority Date	Filing Date	Title
PCT/IB2003/004573 WO2004024919A1 (fr)	2002-09-13	2003-09-11	Oligonucleotides antiviraux non complementaires de sequence
US58462704P	2004-06-06	2004-06-06
PCT/IB2004/003740 WO2005025487A2 (fr)	2003-09-11	2004-09-10	Oligonucleotides ciblant les maladies a prions

Publications (2)

Publication Number	Publication Date
EP1667695A2 EP1667695A2 (fr)	2006-06-14
EP1667695A4 true EP1667695A4 (fr)	2007-01-31

Family

ID=34315467

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
EP04787566A Withdrawn EP1667695A4 (fr)	2003-09-11	2004-09-10	Oligonucleotides ciblant les maladies a prions

Country Status (4)

Country	Link
EP (1)	EP1667695A4 (fr)
AU (1)	AU2004271807A1 (fr)
CA (1)	CA2538245A1 (fr)
WO (1)	WO2005025487A2 (fr)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
WO2006119643A1 (fr) *	2005-05-12	2006-11-16	Replicor Inc.	Molecules contre l'angiogenese oculaire et leurs utilisations
WO2006122409A1 (fr) *	2005-05-16	2006-11-23	Replicor Inc.	Molecules antimicrobiennnes et leur utilisation
WO2006130949A1 (fr) *	2005-06-08	2006-12-14	Replicor Inc.	Molecules contre des maladies liees a l'amyloide et leur utilisation
WO2007036016A1 (fr) *	2005-09-29	2007-04-05	Replicor Inc.	Molécules thérapeutiques et leurs utilisations
JP2009511023A (ja) *	2005-10-06	2009-03-19	ユニバーシティー、オブ、デラウェア	ハンチントン病の治療のためのｇに富むポリヌクレオチド
US11166976B2 (en)	2018-11-08	2021-11-09	Aligos Therapeutics, Inc.	S-antigen transport inhibiting oligonucleotide polymers and methods

Citations (2)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
EP1333090A1 (fr) *	2002-02-01	2003-08-06	NascaCell GmbH	Aptameres specifiques pour proteines de prion
WO2004024919A1 (fr) *	2002-09-13	2004-03-25	Replicor, Inc.	Oligonucleotides antiviraux non complementaires de sequence

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
ES2171231T3 (es) *	1995-10-26	2002-09-01	Winnacker Ernst Ludwig Prof	Moleculas de acido nucleico capaces de distinguir prpc y prpsc de las proteinas prionicas y los procesos para su produccion.
GB0012054D0 (en) *	2000-05-18	2000-07-12	Isis Innovation	Ligands

2004
- 2004-09-10 WO PCT/IB2004/003740 patent/WO2005025487A2/fr not_active Ceased
- 2004-09-10 EP EP04787566A patent/EP1667695A4/fr not_active Withdrawn
- 2004-09-10 CA CA002538245A patent/CA2538245A1/fr not_active Abandoned
- 2004-09-10 AU AU2004271807A patent/AU2004271807A1/en not_active Abandoned

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
EP1333090A1 (fr) *	2002-02-01	2003-08-06	NascaCell GmbH	Aptameres specifiques pour proteines de prion
WO2004024919A1 (fr) *	2002-09-13	2004-03-25	Replicor, Inc.	Oligonucleotides antiviraux non complementaires de sequence

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
CORDEIRO Y ET AL: "DNA converts cellular prion protein into the beta-sheet conformation and inhibits prion peptide aggregation", JOURNAL OF BIOLOGICAL CHEMISTRY, AMERICAN SOCIETY OF BIOLOCHEMICAL BIOLOGISTS, BIRMINGHAM,, US, vol. 276, no. 52, 28 December 2001 (2001-12-28), pages 49400 - 49409, XP002196440, ISSN: 0021-9258 *
SETHI ET AL: "Postexposure prophylaxis against prion disease with a stimulator of innate immunity", LANCET THE, LANCET LIMITED. LONDON, GB, vol. 360, no. 9328, 20 July 2002 (2002-07-20), pages 229 - 230, XP005061830, ISSN: 0140-6736 *

Also Published As

Publication number	Publication date
WO2005025487A3 (fr)	2005-12-01
AU2004271807A1 (en)	2005-03-24
WO2005025487A2 (fr)	2005-03-24
EP1667695A2 (fr)	2006-06-14
WO2005025487A9 (fr)	2006-06-22
CA2538245A1 (fr)	2005-03-24

Publication	Publication Date	Title
GB0322880D0 (en)	2003-10-29	Purchasing scheme
GB0312309D0 (en)	2003-07-02	Targeted liposome
IL173280A0 (en)	2006-06-11	Otoscope
ZA200605863B (en)	2008-01-30	PEF-TU expression units
EP1614386A4 (fr)	2010-05-19	Appareil d'echographie
GB0327384D0 (en)	2003-12-31	Gene therapy
GB0316889D0 (en)	2003-08-20	Pharmaceutical agents
ZA200605862B (en)	2008-06-25	PGRO Expression Units
EP1667695A4 (fr)	2007-01-31	Oligonucleotides ciblant les maladies a prions
GB0308968D0 (en)	2003-05-28	Medicaments
GB0314733D0 (en)	2003-07-30	Medicaments
GB2401043B (en)	2007-10-17	Drug
GB2398992B (en)	2006-06-28	Underwear
GB0326728D0 (en)	2003-12-17	Target
IL176603A0 (en)	2006-10-31	Targeted immunogens
IL172407A0 (en)	2006-04-10	Dna-based aptamers for human cathepsin g
GB0302315D0 (en)	2003-03-05	Novel therapeutic target
GB0315993D0 (en)	2003-08-13	Peptide-based linker
GB0320243D0 (en)	2003-10-01	Body armour
GB0310243D0 (en)	2003-06-11	Target
EP1624073A4 (fr)	2006-05-17	Medicament
GB0100702D0 (en)	2001-02-21	Prion related diseases
GB0320952D0 (en)	2003-10-08	Targeted delivery
GB0325021D0 (en)	2003-12-03	Therapeutic combinations
GB0312982D0 (en)	2003-07-09	Pavement advertiser

Legal Events

Date	Code	Title	Description
2006-05-12	PUAI	Public reference made under article 153(3) epc to a published international application that has entered the european phase	Free format text: ORIGINAL CODE: 0009012
2006-06-14	17P	Request for examination filed	Effective date: 20060329
2006-06-14	AK	Designated contracting states	Kind code of ref document: A2 Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LI LU MC NL PL PT RO SE SI SK TR
2006-06-14	AX	Request for extension of the european patent	Extension state: AL HR LT LV MK
2006-07-26	R17D	Deferred search report published (corrected)	Effective date: 20060622
2006-12-20	DAX	Request for extension of the european patent (deleted)
2007-01-31	A4	Supplementary search report drawn up and despatched	Effective date: 20070104
2007-01-31	RIC1	Information provided on ipc code assigned before grant	Ipc: A61K 31/7088 20060101AFI20051208BHEP
2007-07-25	17Q	First examination report despatched	Effective date: 20070621
2009-06-24	R17C	First examination report despatched (corrected)	Effective date: 20070621
2010-03-19	STAA	Information on the status of an ep patent application or granted ep patent	Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN
2010-04-21	18D	Application deemed to be withdrawn	Effective date: 20091023